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Abstract
Nuclease colicins bind their target receptor BtuB in the outer membrane of sen-
sitive Escherichia coli cells in the form of a high-affinity complex with their cog-
nate immunity proteins. The release of the immunity protein from the colicin
complex is a prerequisite for cell entry of the colicin and occurs via a process
that is still relatively poorly understood. We have previously shown that an
energy input in the form of the cytoplasmic membrane proton motive force is
required to promote immunity protein (Im9) release from the colicin E9/Im9
complex and colicin cell entry. We report here that engineering rigidity in the
structured part of the colicin translocation domain via the introduction of
disulfide bonds prevents immunity protein release from the colicin complex.
Reduction of the disulfide bond by the addition of DTT leads to immunity
protein release and resumption of activity. Similarly, the introduction of a
disulfide bond in the DNase domain previously shown to abolish channel for-
mation in planar bilayers also prevented immunity protein release. Importantly,
all disulfide bonds, in the translocation as well as the DNase domain, also abol-
ished the biological activity of the Im9-free colicin E9, the reduction of which
led to a resumption of activity. Our results show, for the first time, that confor-
mational flexibility in the structured translocation and DNase domains of a
nuclease colicin is essential for immunity protein release, providing further evi-
dence for the hypothesis that global structural rearrangement of the colicin
molecule is required for disassembly of this high-affinity toxin-immunity
protein complex prior to outer membrane translocation.
Introduction
Nuclease colicins are Escherichia coli bacteriocins which
have to traverse two membranes in order to gain access
to their site of action, the cytoplasm. They bind sensitive
cells via the vitamin B12 receptor BtuB receptor in the
outer membrane (OM) and much progress has been
made to unravel the events leading to OM translocation
of their cytotoxic domains (Cascales et al. 2007;
Kleanthous 2010; Jakes and Cramer 2012). In common
with most colicins, the DNase-type colicin E9 (colE9)
consists of three functional domains. The killing activity
is contained in its C-terminal DNase domain; the central
receptor-binding (R) domain binds the BtuB in the OM,
while the N-terminal translocation (T) domain engages
the cellular energy transducing Tol system in order to
achieve OM translocation of its cytotoxic domain. Upon
synthesis colE9 forms a high-affinity interaction with its
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cognate immunity protein, Im9, also encoded by the coli-
cin operon (Kleanthous and Walker 2001), that protects
colicin-producing cells against DNA damage and potential
suicide prior to the release of the complex in the
environment.
The T domain of colE9 consists of residues 1–315 and
has two components: the first 83 residues, commonly
referred to as the intrinsically unstructured T domain
(IUTD) because of a lack of secondary structure and a
large degree of flexibility, contain the OmpF- and TolB-
binding sites (Collins et al. 2002; Tozawa et al. 2005; Lof-
tus et al. 2006; Housden et al. 2010), and a globular
region or structured T domain (STD) from residues 84–
315 that consists of three b-sheets flanked by two helical
segments, forming a jellyroll structure (see Fig. 1; Soelai-
man et al. 2001). The colE9 IUTD recruits the OM trans-
locator OmpF via a process called “directed epitope
delivery” in which two OmpF-binding sites, OBS1 (resi-
dues 2–18) and OBS2 (residues 54–63), penetrate the
lumen of the OmpF trimer sequentially to access the cell
periplasm. The TolB-binding epitope (TBE), sandwiched
between OBS 1 and 2, subsequently interacts with TolB
to harness the cellular energy in order to promote immu-
nity protein release and cell entry of the cytotoxic domain
(Housden et al. 2005, 2010; Yamashita et al. 2008; Bonsor
et al. 2009).
Few studies have addressed the role of the STD in
colicin translocation. In the RNase colE3 this region par-
ticipates in the interaction with its immunity protein
(Im3) in such a way that Im3 is sandwiched between the
RNase and T domain, with 38% of its buried surface
contacting the T domain (Soelaiman et al. 2001). It is
currently unclear whether a similar scenario exists for
colE9, as results from interaction studies with the full-
length protein or its isolated DNase domain suggested
limited involvement of the T domain in the interaction
with Im9 (Wallis et al. 1995). We have previously dem-
onstrated through the engineering of protease cleavage
sites in the STD of colE9 that this region remains largely
accessible to the extracellular environment in the recep-
tor-bound, disulfide-bonded, colE9/Im9 complex (Zhang
et al. 2008).
The nature of the complex formation between colE9
and Im9 and other colicin/immunity complexes has been
well characterized, in contrast to the molecular mecha-
nisms that govern the loss of the immunity protein from
the colicin complex, a prerequisite for cell entry of the
DNase domain. We and others have previously shown
that, receptor binding and OmpF recruitment, in isola-
tion, are insufficient to promote immunity protein release
(Housden et al. 2005; Zhang et al. 2008). In contrast,
translocation of the IUTD of colE3 through OmpF has
been claimed to promote Im3 release through a weaken-
ing of its binding interface with the T domain (Zakharov
et al. 2006, 2008). Additionally, a requirement for the
cytoplasmic membrane proton motive force as the energy
source for Im9 release from the colE9/Im9 complex was
demonstrated, with the Tol proteins being involved in
transducing this energy to the OM (Bonsor et al. 2009;
Vankemmelbeke et al. 2009).
Unfolding of nuclease colicins to enable cell entry has
been inferred from several observations: (i) some loss of
helical structure at the distal ends of the 135-residue colE3
receptor-binding domain when bound to BtuB (Kurisu
et al. 2003); (ii) the inhibition of colE9 biological activity
by an engineered disulfide bond across the extreme end of
its receptor-binding domain, which was reversible by
dithiothreitol (DTT) treatment (Penfold et al. 2004); (iii)
the requirement for the loss of the Im3-translocation
domain interaction in colE3-Im3 (Walker et al. 2003); and
(iv) a small increase (~8 A) in the distance between the
translocation and nuclease domains of colE3 upon BtuB or
OmpF recruitment, observed by in vitro Fluorescence reso-
nance energy transfer (FRET) analysis (Zakharov et al.
2008). In contrast, analysis of the interaction of the colE9
disulfide-bonded receptor-binding domain with BtuB
revealed similar thermodynamic parameters compared to
the wild-type protein suggesting that receptor binding
alone does not induce gross conformational rearrange-
ment of the colicin receptor-binding domain (Housden
et al. 2005).
Figure 1. Schematic representation of the domain arrangement of
colE9 showing the positions of the disulfide bonds that have been
generated in the STD, R, and DNase domains (see Table 1) and the
crystal structure of colE3 from residues 84–315 (Soelaiman et al.
2001) that depict the STD with the locations of the corresponding
cysteine mutations and consequent disulfide bond formation in the
STD of colE9 for IL1 and IL3.
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Although translocation-induced protein unfolding is
now generally accepted in the fields of toxin biology and
protein secretion, there remains considerable uncertainty
about the nature of the unfolding events associated with
colicin import and how this impacts on immunity pro-
tein release. Recent work by David Brockwell and col-
leagues have unraveled the paradox that exists between
rapid Immunity protein release from the nuclease
domains of enzymatic colicins at the cell surface and the
perceived astronomical forces needed to achieve this feat
(Farrance et al. 2013). Using Atomic Force Microscopy
and disulfide bond linkages of the isolated DNase/immu-
nity domains, they showed that rapid E9DNase:Im9 dis-
sociation occurs following the application of only a small
force across the complex that generates localized confor-
mational rearrangements leading to changes in the
energy landscape of the interaction and destabilization of
the complex (Farrance et al. 2013). We show here
through the engineering of disulfide-induced rigidity into
the STD and DNase domain of colE9 that a global con-
formational rearrangement of the colicin molecule
extending beyond the DNase domain is required in order
to release its immunity protein. Additionally, the disul-
fide bonds in the immunity-free colicin inhibited cell
killing activity without impacting on in vitro catalytic
activity, suggesting that the unfolding initiated by OM
translocation of the colicin IUTD is transduced along
the entire molecule in order to achieve cellular uptake of
the DNase domain.
Material and Methods
Plasmids, bacterial strains, and media
Escherichia coli DH5a was used as the host strain for
cloning and mutagenesis. Escherichia coli BL21 (DE3)
(Novagen, Merck Millipore, Darmstadt, Germany) were
used as the host strain for the expression vector pET21a
(Novagen), which has a strong, IPTG-inducible T7 poly-
merase promoter and a C-terminal polyhistidine tag (His-
tag) to facilitate the purification of overexpressed pro-
teins. The reporter strain E. coli DPD1718 has been
described previously (Vankemmelbeke et al. 2005). Esc-
herichia coli strain LMG194 (Invitrogen Life Technologies,
Paisley, U.K.) containing a lacZ deletion (F-DlacZ74 galE
thi rpsL DphoA (PvuII) Dara714 leu:Tn10) and trans-
formed with pAG1 was used for the immunity protein
release experiments. Plasmid pAG1 is derived from
pML261 and contains a 2.4-kb EcoRI-HindIII fragment
that encodes the complete btuB gene in the vector pUC8
(Koster et al. 1991). All cultures were routinely grown in
Luria-Bertani (LB) broth, or on plates of LB agar, supple-
mented where required with ampicillin (100 lg mL1) or
chloramphenicol (30 lg mL1).
All colicin constructs (Table 1) are derived from plasmid
pNP69 encoding the colicin E9 structural gene (ceaI) and
the Im9 immunity gene (ceiI) followed by a C-terminal
His-tag, under the control of an inducible T7 promoter in
pET21a (Penfold et al. 2004). Single cysteine mutations
were introduced using the megaprimer mutagenesis
approach (Garinot-Schneider et al. 1996) and double cyste-
ine-containing constructs were generated via restriction
digest with the unique AatII site within the colicin
sequence. Plasmid pBH29 and pKM1 (Table 1) contain
two cysteine mutations in the colE9 R and DNase domain,
respectively (Mosbahi et al. 2002; Penfold et al. 2004).
Protein purification
ColE9/Im9 complexes were purified by metal chelate
chromatography with phosphate-buffered saline pH 7.4
(PBS) elution buffer containing 500 mmol/L NaCl and
1 mol/L imidazole. Where necessary, the immunity pro-
tein was removed from the colicin complex as previously
described (Vankemmelbeke et al. 2012). The free colicin
proteins were then refolded by dialysis against PBS con-
taining 1 mmol/L DTT and stored. The labeled immunity
protein for the Im9 release experiments was purified and
labeled as previously described (Vankemmelbeke et al.
2009).
Diamide oxidation and DTT reduction
For diamide oxidation, the protein samples were dialyzed
overnight against PBS to remove the DTT. Protein sam-
ples were then adjusted to 1 mmol/L with diamide and
incubated for 30 min in the dark at room temperature,
before extensive dialysis against PBS. For reduction, the
protein samples were incubated with 10 mmol/L DTT for
1 h at ambient temperature followed by extensive dialysis
against degassed PBS. To avoid the possibility of sponta-
neous oxidation during certain assays, reduced protein
Table 1. Cysteine-containing colicin E9 constructs.
Name
Cysteine
mutations
Location of
S-S bond Reference
pBH29 Y324C-L447C Receptor-binding
domain
Penfold et al. (2004)
pIL1 S96C-S246C Structured T
domain
This work
pIL3 A86C-A228C Structured T
domain
This work
pKM1 D468C-E514C DNase Domain Mosbahi et al. (2002)
ª 2013 The Authors. MicrobiologyOpen published by John Wiley & Sons Ltd. 855
M. Vankemmelbeke et al. Immunity Protein Release From Enzymatic Colicins
was alkylated using iodoacetamide (50 mmol/L, final con-
centration) followed by extensive dialysis against PBS.
Colicin activity assays
The lux reporter assay for DNA damage was used to test
the activity of wild-type and mutant colicin constructs
(Vankemmelbeke et al. 2005). All the assays were done as
described previously. Gamma values for the luminescence
induction by each colicin were calculated and the activi-
ties of the mutant proteins presented as a percentage of
the wild-type activity (obtained by comparing the lumi-
nescence induced by the mutant colicins to that of the
wild-type E9 colicin). DNA cleavage assays using linear-
ized pUC18 DNA were performed on free colicin proteins
to check for DNase activity as previously described
(Wallis et al. 1992).
Analytical gel filtration
Analytical gel filtration to detect colicin-OmpF and coli-
cin-TolB complex formation was performed on a Superdex
200 10/300 GL column (GE Healthcare Life Sciences,
Buckinghamshire, U.K.) equilibrated in 20 mmol/L potas-
sium phosphate, pH 6.5 in the presence of 1% (w/v) n-oc-
tyl-b-D-glucopyranoside at 22°C. Protein solutions were
buffer exchanged into the gel filtration buffer using a 5 mL
HiTrap desalting column (GE Healthcare). Samples of
30 lmol/L colicin, 30 lmol/L TolB, 15 lmol/L OmpF tri-
mer, 30 lmol/L colicin + 30 lmol/L TolB, and 30 lmol/L
colicin + 15 lmol/L OmpF were injected as 200 lL aliqu-
ots onto the column and eluted at a flow rate of 0.5 mL/
min, monitoring the absorbance of the eluate at 280 nm.
Immunity protein release assay
The assay was performed as previously described (Van-
kemmelbeke et al. 2009). Briefly, wild-type E. coli
LMG194 (pAG1) from overnight cultures were grown to
mid-log (OD600 nm ~0.4–0.6) in M9 minimal medium
containing 0.2% (w/v) glucose and casamino acids.
ColE9/Alexa Fluor-labeled Im9 (Im9AF) complexes were
formed by preincubation of oxidized Im9-free colE9 con-
structs with Im9AF at a molar ratio of 1:1.5 and were sub-
sequently added to 1 mL of cells in duplicate (10 nmol/L
final concentration). The release of Im9AF in the medium
after 30 min at 37°C (DTT-treated and control cells [in
the absence of reducing agent]) was measured using a
Victor2 1420 multilabel plate reader (Wallac, Perkin
Elmer Wallac, Buckinghamshire, U.K.), after analysis of
the cell-bound relative fluorescence units (RFU). Error
bars represent the means  SEM of three independent
experiments.
Results and Discussion
Characterization of the disulfide-containing
colicin E9 T domain constructs
At present, the extent of unfolding of a receptor-bound
nuclease colicin conducive to immunity protein release
and the role of the STD in this process are unclear. We
decided to investigate these ambiguities by introducing
conformational constraint in the STD of the colE9
through disulfide bond engineering and analyzing their
effect on Im9 release during OM translocation and on
colicin biological activity.
We introduced disulfides at two flexible loop locations
in the STD of colE9 (constructs pIL1 and pIL3, Table 1
and Fig. 1). Locations for the introduction of the single
cysteine mutations were identified using the coordinates
of colE3 (pdb:1JCH, [Soelaiman et al. 2001]) as template
for colE9 and the program S-S bond (http://eagle.mmid.
med.ualberta.ca/forms/ssbond.html) which selects residues
with beta carbons between 3.42 and 4.24 A˚ apart.
Although colE9 has one extra residue (at residue 126 of
colE9) over its T and R domains compared to colE3,
colE9 and colE3 have 91.8% identity over their STD indi-
cating significant conservation of residues over this
region. Those residues chosen with supporting chemistries
for disulfide bond formation were Ala96 and Ala245
(Ala246 in colE9), and Ser86 and Ser227 (Ser228 in
colE9) according to Table 1. The presence of all cysteine
mutations in the colicin constructs was confirmed
through DNA sequencing and killing assays on the single
cysteine mutants showed that the mutations had no affect
on their biological activity (data not shown). The double
cysteine-containing colicin constructs were generated via
restriction digest and the resulting proteins purified.
Disulfide bond formation upon oxidation was confirmed
by differential reactivity with the thiol-specific Ellman’s
reagent of the free oxidized and reduced colicin con-
structs (data not shown). Size-exclusion chromatography
of the oxidized constructs on a Superdex-75 10/300 GL
(GE healthcare) column and sodiumdodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) confirmed
their predominant monomeric nature (data not shown).
In order to verify that the disulfide bonds had not unduly
abolished catalytic activity of the nuclease colicin, we per-
formed an in vitro DNA cleavage assay. The results show
that the oxidized free constructs cleave DNA as efficiently
as the reduced and alkylated proteins (Fig. 2A).
Two previously characterized colE9 constructs, pBH29
and pKM1, contain a disulfide bond in the R and DNase
domain, respectively (Table 1), which reversibly affect
their biological activity (Mosbahi et al. 2002; Penfold
et al. 2004). The biological activity of all four reduced
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and alkylated constructs (BH29, R domain; KM1, DNase
domain and IL1 and IL3, STD) was analyzed using our
lux assay for DNA damage (Vankemmelbeke et al. 2005).
The two new constructs (IL1 and IL3) and KM1 exhibited
between 70% (IL3 and KM1) and 84% (IL1) of the activ-
ity of reduced and alkylated BH29 (Fig. 2B), indicating
that the introduced cysteine mutations had not compro-
mised biological activity, further confirming the DNA
cleavage results.
Disulfide bonds in the STD and DNase
domains inhibit Im9 release from receptor-
bound colicin E9/Im9 constructs
Earlier work by our group and colleagues has shown that
an input of cellular energy, in the form of the cytoplas-
mic membrane proton motive force, is required in order
to release the Im9 protein from a cell-bound colE9/Im9
complex and initiate OM translocation of the DNase
domain (Bonsor et al. 2009; Vankemmelbeke et al.
2009). The underlying structural transitions enabling
these two events and the degree of unfolding of the coli-
cin molecule are currently not clearly defined. We envis-
aged that the energy input would be utilized for the
unfolding of the receptor-bound colicin which would
destabilize its interaction with the immunity protein,
bringing about its expulsion, in preparation for OM
translocation of the DNase domain. We decided to test
this hypothesis by analyzing the effect of the disulfide
bonds in the STD (IL1 and IL3) and DNase domains
(KM1) of colE9 on Im9 release. We used the previously
characterized construct containing the disulfide in the
R domain of colE9 (BH29) as the control in these exper-
iments.
Disulfide-containing colicin complexes with Alexa
Fluor-labeled Im9 protein were preformed (Van-
kemmelbeke et al. 2009) and incubated with sensitive cells
as described in Material and Methods. In the absence of
reducing agent, all constructs, including BH29, showed a
similar background Im9 release which we have previ-
ously attributed to incomplete oxidation of the disulfide-
containing constructs (Vankemmelbeke et al. 2005, 2009),
(a) (b)
Figure 2. Validation of the in vitro and in vivo DNA cleavage activity of the STD constructs. (A) DNA cleavage activity of the Im9-free STD colicin
constructs showing 125 ng of NdeI linearized untreated pUC18 (lane 1) and its cleavage by the DNase activity of reduced and alkylated IL1 (lane
2), oxidized IL1 (lane 3), reduced and alkylated IL3 (lane 4), and oxidized IL3 (lane 5). (B) DNA damage-induced luminescence (relative
luminescence units [RLU]) in Escherichia coli DPD1718 cells by incubation with 4 nmol/L reduced and alkylated IL1 (s), IL3 (♢), KM1 (D), BH29
(h), and LB medium (9).
Figure 3. Immunity protein release (Im9AF) from oxidized disulfide –
containing colE9 constructs. Release of immunity protein following
reduction of the disulfide bond is shown as relative fluorescence units
(RFU) between Escherichia coli LMG194 (pAG1) cells preincubated
with 10 nmol/L of each oxidized colicin E9 construct in the presence
(black bars) and absence (white bars) of 2 mmol/L DTT after a 30-min
incubation period at 37°C.
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giving rise to a small amount of background activity
(see Fig. 5) and hence immunity protein release. Addition
of DTT led to a twofold increase in Im9 release for all
constructs with the exception of KM1 for which the
DTT-induced release was somewhat less (Fig. 3). It is
possible that the disulfide in cell-bound KM1 is less acces-
sible to DTT reduction; alternatively, the reduced thiols
may readily reoxidize in the cell-bound construct (Mos-
bahi et al. 2002).
This is the first time that flexibility within the STD has
been shown necessary for immunity protein release from a
nuclease colicin complex despite the low forces required at
the N terminus to activate the “trip bond” effect and disso-
ciate immunity from the colicin complex (Farrance et al.
2013). Both disulfides in the STD (IL1 and IL3) have a sim-
ilar inhibitory effect on Im9 release, in spite of the disulfide
in IL3 being closer to the IUTD region than in IL1 and per-
haps exhibiting different unfolding characteristics. As out-
lined in the introduction, there is some ambiguity about
the location of Im9 in the colE9/Im9 complex. If Im9 is
centered between the DNase and STD, analogous to the
orientation of the colicin E3/Im3 complex (Soelaiman et al.
2001), then one could envisage that introducing rigidity
into the latter would have a knock-on effect on immunity
protein release. Evidence to support this model, however, is
currently lacking, as it is equally plausible that Im9 resides
on the external side of the colE9/Im9 complex. Intriguingly,
Im9 release remains hindered by the disulfide in the DNase
domain suggesting that unfolding of the STD and R
domains in isolation are insufficient to dislodge the immu-
nity protein, perhaps supporting the latter model. We sug-
gest that a conformational rearrangement requiring a
cellular energy input and initiated via the recruitment of
the Tol system by the colicin IUTD is propagated along the
STD (IL1 and IL3), R domain (BH29), and finally DNase
domain (KM1) culminating in the release of the immunity
protein. The proximity of the OM surface may also
contribute to this process, providing electrostatic attraction
of the positively charged DNase and repulsion of the nega-
tively charged immunity protein (Walker et al. 2007;
Vankemmelbeke et al. 2012).
Locked colicin with disulfide bonds in the
STD still interact with OmpF and TolB
Although the biological data above suggests that the disul-
fide locked IL1 and IL3 proteins interact with BtuB, it is
possible that the inactivity of the mutants is due to their
inability to bind directly to OmpF and/or TolB per se
rather than any inability to bind to OmpF and/or TolB in
vivo due to structural frustration inflicted on the colicins
by the disulfide bonds. Analytical gel filtration showed that
Figure 4. Analytical gel filtration showing
oxidized IL1 and IL3 interact with OmpF and
TolB. Absorbance (A280) measurements over
elution volume are shown for IL1 (left panel),
IL3 (right panel), with from top to bottom:
single IL1/3 constructs, OmpF and TolB,
followed by mixtures of IL1/3 constructs with
OmpF, and IL1/3 with TolB. A shift in retention
time of complexed proteins of IL1::OmpF and
IL1::TolB, IL3::OmpF and IL3::TolB (fourth and
fifth panels, respectively) is shown at the top
of the figure.
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both disulfide locked IL1 and IL3 colicins still had the pro-
pensity to interact with both OmpF and TolB in vitro cor-
roborating our conclusions that global conformational
rearrangements along the entire colicin are necessary for
biological activity (Fig. 4). Conformational flexibility is
essential for the passage of the colE9 IUTD through the
lumen of the OmpF trimer and formation of the translocon
complex (Yamashita et al. 2008). The colE9 translocon
involves the simultaneous interaction of the porin-binding
sequences, OBS1 and OBS2, of the IUTD with two of the
three subunits of OmpF enabling binding of the TolB-TBE
with TolB in a fixed orientation (Housden et al. 2013). This
sequence of events facilitates the connection of the colicin
with the proton motif force, release of Im9, and subsequent
cell entry (Vankemmelbeke et al. 2009). It is uncertain to
what extent the disulfide bonds in IL1 and IL3, once bound
to BtuB, place a conformational restraint on the threading
of the IUTD through the OmpF porin even though an
interaction with OmpF and TolB is seen in vitro but a
disulfide bond engineered into the top of the receptor-
binding domain of colE9 did not hinder occlusion of the
IUTD by OmpF (Zhang et al. 2008).
Biological activity is reversibly inhibited in
the oxidized colicin E9 constructs, following
Im9 removal
Construct BH29 has been used in the past for cell killing
synchronization purposes (Penfold et al. 2004; Housden
et al. 2005; Zhang et al. 2008; Vankemmelbeke et al.
2009). Im9-free BH29 is inactive when bound to sensitive
cells in oxidized form, resuming activity upon reduction
of the disulfide bond by DTT. In order to find out
whether the disulfide bonds in the Im9-free STD con-
structs (IL1 and IL3) would prevent biological activity in
a similar manner, we analyzed the killing activity of the
oxidized constructs in the absence of Im9 using our sensi-
tive lux assay (Vankemmelbeke et al. 2005).
Both disulfide bonds in the STD impeded cell killing,
which was reversed by the addition of reducing agent, in
analogy to the disulfide bond in the R and DNase domain
(Fig. 5). All oxidized constructs showed a small amount of
background activity which could be due to trace amounts
of reduced or multimeric protein in the oxidized protein
preparations. The data clearly show that intradomain disul-
fides in any of the three structural colicin domains inhibit
biological activity, consistent with domain unfolding and/
or the use of a restricting protein channel being mandatory
for immunity release and concomitant colicin OM translo-
cation. This confirms earlier observations by Duche (2007)
showing that the colicin E2 R and T domains maintain
contact with their binding partners at the OM and periplas-
mic space, respectively, when the DNase domain gains
access to the cytoplasm, an arrangement most likely
to result in the unfolding of the colicin (Duche´ 2007).
A recent report on the distantly related Yersinia pestis bacte-
riocin, pesticin, equally established an intricate link
between unfolding and cellular import through disulfide
bond engineering (Patzer et al. 2012).
Conclusion
Previously, rigidity engineered into the receptor binding
and IUTD domains of colE9 through the establishment of
disulfide bonds have prevented immunity release and
biological activity of cell-bound colE9 (Penfold et al.
2004; Zhang et al. 2008). We extend these results and
show that disulfide bonds produced in the globular
translocation and DNase domains similarly prevent
immunity release with a concomitant detoxifying effect in
vivo. These observations suggest that the unfolding
requirement is likely to be a general principle for bacte-
riocin OM translocation and may provide an explanation
for the tendency of bacteriocins to hijack cellular energy
transducing systems (Jakes and Cramer 2012). This would
enable the toxins to make use of the cellular energy, ATP
or the inner membrane-associated proton motive force as
a source of free energy to promote mechanical unfolding
and membrane translocation (Thoren and Krantz 2011).
The recent finding that colicin:immunity protein dissocia-
tion occurs at relatively low applied forces (≤20 pN) and
within the energy ranges generated by the proton motive
force (Farrance et al. 2013; Robinson 2013), provides fur-
ther evidence for the role of internal cellular energy
systems in external transport processes.
Figure 5. Disulfide bonds reversibly inhibit cell killing by oxidized
Im9-free colE9 constructs. The luminescence induced in Escherichia
coli DPD1718 cells preincubated, in duplicate, with 4 nmol/L oxidized
colicin E9 constructs, IL1 (s), IL3 (◊), KM1 (D), BH29 (h) and 4 nmol/
L oxidized and then reduced colE9 constructs, IL1 (●), IL3 (♦), KM1
(▲), BH29 (&) following addition of 1 mmol/L DTT after 1 min, or
with no addition (x) is shown with time.
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